Loading
Life sciences · Journal article
Frontiers in Pharmacology · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction Trastuzumab deruxtecan (T-DXd) has been approved for the second-line therapy of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer, revolutionizing the treatment landscape for this clinical scenario. Case Presentation Given the lack of real-world evidence, here we reported a patient with HER2-positive, metastatic gastroesophageal junction adenocarcinoma treated with T-DXd in the second-line setting. The patient, a 63-year-old male, previously received first-line treatment with trastuzumab plus oxaliplatin, capecitabine and sintilimab but disease progression occurred at 4.5 months. He subsequently received T-DXd-based therapy for a total of 22 treatment cycles and achieved a progression-free survival (PFS) of 23 months, with improved performance status and no T-DXd treatment dose reduction during treatment. Conclusion This case firstly supplements the real-world data of T-DXd for patients with HER2-positive advanced gastric cancer in the second-line setting. These data indicate the PFS benefit with second-line T-DXd-based treatment even after rapid progression on trastuzumab-based therapy and the safety of full-dose T-DXd during long-course treatment.